DiaMedica Therapeutics Inc. (DMAC)
- Previous Close
4.0000 - Open
4.1600 - Bid 3.8200 x 100
- Ask 3.9200 x 100
- Day's Range
3.8200 - 4.1600 - 52 Week Range
2.1400 - 6.8184 - Volume
61,232 - Avg. Volume
92,115 - Market Cap (intraday)
165.423M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6000 - Earnings Date May 7, 2025 - May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.75
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
www.diamedica.comRecent News: DMAC
View More
Performance Overview: DMAC
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DMAC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DMAC
View MoreValuation Measures
Market Cap
165.42M
Enterprise Value
121.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.06
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.18%
Return on Equity (ttm)
-53.27%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.44M
Diluted EPS (ttm)
-0.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
44.15M
Total Debt/Equity (mrq)
0.83%
Levered Free Cash Flow (ttm)
-11.68M